PMID- 21079885
OWN - NLM
STAT- MEDLINE
DCOM- 20110801
LR  - 20211020
IS  - 1528-3658 (Electronic)
IS  - 1076-1551 (Print)
IS  - 1076-1551 (Linking)
VI  - 17
IP  - 3-4
DP  - 2011 Mar-Apr
TI  - Dynamic expression of Qa-2 during acute graft rejection.
PG  - 248-55
LID - 10.2119/molmed.2010.00133 [doi]
AB  - Human leukocyte antigen (HLA)-G exhibits immunotolerogenicity and is related to 
      allograft acceptance. Qa-2 is the murine homolog of HLA-G; it has structure and 
      functions similar to those of HLA-G. We investigated the dynamic expression of 
      Qa-2 in skin allografts by immunohistochemistry and on peripheral blood 
      lymphocyte subsets by flow cytometry during the entire process of acute graft 
      rejection (AGR) with a murine skin transplantation model to determine its 
      relationship with the pathological changes of allografts and the influence of 
      immunosuppressive therapy. In grafts without immunosuppressive treatment, Qa-2 
      did not exhibit obvious changes in syngeneic and allogeneic recipients. In 
      contrast, with immunosuppressant-treated grafts, positive expression of Qa-2 was 
      observed. It remained at high levels in the immunosuppressant-treated syngeneic 
      group; however, it became weakly positive and even negative in infiltrating 
      inflammatory cells as AGR advanced, but it remained strongly positive in other 
      skin tissues throughout the AGR process. Qa-2 expression on CD4(+) and CD8(+) 
      peripheral blood lymphocyte subsets remained stable at a normal level in the 
      non-immunosuppressant-treated syngeneic group. Immunosuppressive treatment can 
      also significantly upregulate Qa-2. In the allogeneic groups, decreased 
      expression was observed when AGR was at histological grades 1 to 2 (well before 
      gross rejection was observed). Qa-2 was upregulated again after the graft was 
      rejected completely. The results suggest that the increase in Qa-2 may be 
      attributed to the use of immunosuppressive treatments. Moreover, Qa-2 expression 
      decreased significantly with AGR progression, suggesting that it may be a 
      potential marker for predicting AGR, especially in the presence of 
      immunosuppressive agents.
FAU - Lu, Nan
AU  - Lu N
AD  - Institute of Diagnostics, School of Medicine, Shandong University, Jinan, P R 
      China.
FAU - Wang, Chuanxin
AU  - Wang C
FAU - Yang, Xiaojing
AU  - Yang X
FAU - Zhao, Shengmei
AU  - Zhao S
FAU - Li, Xiangdong
AU  - Li X
FAU - Li, Xiaoli
AU  - Li X
FAU - Jiang, Hong
AU  - Jiang H
FAU - Feng, Jinbo
AU  - Feng J
FAU - Zhang, Yi
AU  - Zhang Y
FAU - Zou, Xiong
AU  - Zou X
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20101112
PL  - England
TA  - Mol Med
JT  - Molecular medicine (Cambridge, Mass.)
JID - 9501023
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Q surface antigens)
SB  - IM
MH  - Acute Disease
MH  - Animals
MH  - CD4-Positive T-Lymphocytes/metabolism
MH  - CD8-Positive T-Lymphocytes/metabolism
MH  - Dermatologic Surgical Procedures
MH  - Disease Progression
MH  - Flow Cytometry
MH  - Graft Rejection/etiology/*metabolism/pathology
MH  - Histocompatibility Antigens Class I/*biosynthesis
MH  - Immunohistochemistry
MH  - Immunosuppressive Agents/pharmacology
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Inbred C57BL
MH  - Skin/drug effects/*metabolism
MH  - Skin Transplantation/adverse effects/*methods
MH  - Time Factors
MH  - Transplantation, Homologous
MH  - Transplantation, Isogeneic
PMC - PMC3060991
EDAT- 2010/11/17 06:00
MHDA- 2011/08/02 06:00
PMCR- 2010/11/12
CRDT- 2010/11/17 06:00
PHST- 2010/07/31 00:00 [received]
PHST- 2010/11/09 00:00 [accepted]
PHST- 2010/11/17 06:00 [entrez]
PHST- 2010/11/17 06:00 [pubmed]
PHST- 2011/08/02 06:00 [medline]
PHST- 2010/11/12 00:00 [pmc-release]
AID - molmed.2010.00133 [pii]
AID - 10_133_lu [pii]
AID - 10.2119/molmed.2010.00133 [doi]
PST - ppublish
SO  - Mol Med. 2011 Mar-Apr;17(3-4):248-55. doi: 10.2119/molmed.2010.00133. Epub 2010 
      Nov 12.